Job Description
The Center for Immuno-Oncology (CIO) Translational Research program at the National Cancer Institute (NCI) functions as a multidisciplinary and interdisciplinary translational research programmatic effort with the goal of developing novel immunotherapies and immunotherapeutic strategies for cancer. Focus is placed on the development of novel immunotherapeutics, not only as monotherapies, but more importantly, in combination with other immune-mediating modalities, and other conventional or experimental therapies, as part of an immuno-oncology programmatic effort. Within this effort are several research groups that interact closely with the clinical groups of the CIO, and with collaborators within the NCI intramural and extramural programs, and with investigators in the private sector. As Co-Director of the CIO, Dr. Jeffrey Schlom directs the translational research area of investigation.
The CIO Translatoinal Research program takes advantage of the uniqueness of the NCI intramural program in that it spans high-risk basic discovery research in immunology and tumor biology, through preclinical translational research, to paradigm-shifting clinical trials. Focus is placed on the design and development of novel 'off-the-shelf' recombinant immunotherapeutics and immunomodulators that can be used in clinical studies at numerous institutions. This is accomplished in part via Cooperative Research and Development Agreements (CRADAs) with partners in the private sector. The immunotherapeutics and immune modulators that we have developed have also enabled multiple collaborations with clinical investigators at extramural Cancer Centers.
We are looking for postdoctoral fellows interested in learning immunology and immunotherapy.
The recruitment of postdoctoral fellows is open to U.S. citizens or permanent residents only.
To learn more about the CIO and its research, please refer to the Center for Immuno-Oncology's website and Dr. Schlom's profile page.
Qualifications and Job Details
Required and Preferred Skills
Ph.D., M.D., or equivalent in immunology, molecular/cell biology or experimental pathology.
About the NCI Center for Cancer Research
The Center for Cancer Research (CCR) is home to nearly 250 basic and clinical research groups located on two campuses just outside of Washington, D.C. CCR is part of the National Cancer Institute (NCI) and makes up the largest component of the research effort at the National Institutes of Health (NIH). Centrally supported by long-term funding and a culture of complete intellectual freedom, CCR scientists are able to pursue the most important and challenging problems in cancer research. We collaborate with academic and commercial partners and advocacy groups across the world in efforts to prevent, diagnose and treat cancer and HIV/AIDS. The CCR research portfolio covers the full spectrum of biological and biomedical research. Our work ranges from basic to translational and clinical, and our clinical trials are conducted in the NIH Clinical Center, the world’s largest hospital dedicated to clinical research that offers a robust infrastructure to support CCR’s patients on an estimated 250 open studies. The success of CCR is grounded in an exceptionally strong discovery research program that provides the foundation for the seamless translation of insights from bench to bedside. Read more about CCR, the benefits of working at CCR and hear from our staff on their CCR experiences.
Bethesda
Bethesda is one of the most highly educated communities in the United States and has a nationally renowned school system. The city is a thriving suburban center close to Washington, D.C., and home to many restaurants, retailers and a flourishing arts and entertainment district.
Please send a cover letter describing your research experience and interests, CV including bibliography, and contact information for 3 references to:
Jeffrey Schlom, Ph.D., via e-mail: schlomj@mail.nih.gov
Please write "Postdoctoral application" in the subject heading of the email.
No calls, please. If we are interested, you will be contacted by Dr. Schlom.